https://www.selleckchem.com/pr....oducts/1-deoxynojiri
Patients will be followed over a period of 12 months. The primary outcome is depression severity (PHQ-9) 6 months after screening. Secondary outcomes include patient engagement in mental healthcare, professional depression care and cost-effectiveness. According to a statistical analysis plan, the primary endpoint of all randomised patients will be analysed regarding the intention-to-treat principle. The Ethics Committee of the Hamburg Medical Association approved the study. A clinical trial company will ensure data safety, mo
Like
Comment
Share
